

SUPPLEMENTARY MATERIAL

Table S1. Distribution of symptoms experience by transplant recipients with COVID-19.

Symptom	All patients, n (%)	No oxygen requirement (n = 91), n (%)	Oxygen requirement (n = 69), n (%)
Fever (n = 146)	82 (56.0)	48 (52.7)	34 (49.3)
Sore throat (n = 135)	29 (21.5)	20 (22.0)	9 (13.0)
Cough (n = 142)	84 (59.2)	51 (56.0)	33 (47.8)
Myalgia (n = 135)	50 (37.0)	31 (34.1)	19 (27.5)
Dyspnea (n = 154)	78 (50.6)	23 (25.3)	55 (79.7)
Headache (n = 135)	34 (25.2)	25 (27.5)	9 (13.0)
Rhinorrhea (n = 133)	28 (21.1)	21 (23.1)	7 (10.1)
Nausea/vomiting (n = 133)	34 (25.6)	23 (25.3)	11 (15.9)
Diarrhea (n = 138)	52 (37.7)	27 (29.7)	25 (36.2)
Anosmia (n = 132)	18 (13.6)	15 (16.5)	3 (4.3)
Hypogeusia (n = 131)	23 (17.6)	19 (20.9)	4 (5.8)

Figure S1. Diagram demonstrating the proportion of patients with antibody and viral load testing. SOT, solid-organ transplant.




Figure S2. Correlation between anti-RBD and anti-NP antibody levels at >14 days postdiagnosis. NP, nucleoprotein; RBD, receptor binding domain.

